Nanocarriers for intravenous injection--the long hard road to the market.
about
A comparison of immunotoxic effects of nanomedicinal products with regulatory immunotoxicity testing requirementsNanomilling of Drugs for Bioavailability Enhancement: A Holistic Formulation-Process Perspective.Multivalent polymers for drug delivery and imaging: the challenges of conjugationLipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.Preparation, characterization, and in vitro/vivo studies of oleanolic acid-loaded lactoferrin nanoparticles.Nanoparticle delivery of donor antigens for transplant tolerance in allogeneic islet transplantationOptimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling.Smart Nanoparticles for Drug Delivery: Boundaries and OpportunitiesKey factors which concur to the correct therapeutic evaluation of herbal products in free radical-induced diseases.Enhanced antitumor activity in A431 cells via encapsulation of 20(R)-ginsenoside Rg3 in PLGA nanoparticles.Drug Release and Targeting: the Versatility of Polymethacrylate Nanoparticles for Peroral Administration Revealed by Using an Optimized In Vitro-Toolbox.Bridging laboratory and large scale production: preparation and in vitro-evaluation of photosensitizer-loaded nanocarrier devices for targeted drug delivery.Humid Heat Autoclaving of Hybrid Nanoparticles Achieved by Decreased Nanoparticle Concentration and Improved Nanoparticle Stability Using Medium Chain Triglycerides as a Modifier.pH-Triggered release from surface-modified poly(lactic-co-glycolic acid) nanoparticles.New perspectives in nanotherapeutics for chronic respiratory diseases.Bio-inspired artemether-loaded human serum albumin nanoparticles for effective control of malaria-infected erythrocytes.Nanoencapsulation of ultra-small superparamagnetic particles of iron oxide into human serum albumin nanoparticles.Effect of the excipient concentration on the pharmacokinetics of PM181104, a novel antimicrobial thiazolyl cyclic peptide antibiotic, following intravenous administration to mice.Biopolymer-Based Nanoparticles for Cystic Fibrosis Lung Gene Therapy Studies.Pulmonary Codelivery of Doxorubicin and siRNA by pH-Sensitive Nanoparticles for Therapy of Metastatic Lung Cancer.Duodenum-triggered delivery of pravastatin sodium: II. Design, appraisal and pharmacokinetic assessments of enteric surface-decorated nanocubosomal dispersions.Tailoring Formulations for Intranasal Nose-to-Brain Delivery: A Review on Architecture, Physico-Chemical Characteristics and Mucociliary Clearance of the Nasal Olfactory Mucosa
P2860
Q26744352-34B8CCBC-29E7-4D81-A51D-10BEE6FD8DBBQ26746912-58FA6C9B-95DA-4B0F-87DE-6B17733AC4B4Q27692689-B1175297-C9EB-4FE5-99DF-F97253014BAEQ30366990-6F3CB5AF-C4B4-4371-910C-B9E693415FFAQ33686640-A4B0B826-5AB8-468A-B5FD-81F439697936Q34506806-06E6709B-C739-4496-B10D-3BF4D37E6F7CQ34571360-600E2E73-58F1-493D-8C0C-D2DD075C80C3Q35067230-2527DD15-8213-4B77-950B-6006FA94B94DQ38466709-14B81B51-B3D9-417D-A24C-55E08DD115F2Q38743717-8348F78C-4FC5-4024-A125-989574BD0DBAQ38848809-1C17F88A-AF39-4C0B-B88F-88D6B41C73D4Q38939439-3916AB4D-7813-4442-824D-870B2D686C40Q39717230-7F56B714-153D-4158-8998-09BE8EB7B555Q39991339-8A352EE5-ACBE-4A42-81EA-BF4DDFD07F62Q40039105-F8AF3181-A168-4CD1-9220-A60F548A1782Q40498416-082D303E-E846-428A-BE43-FC824C19FF35Q43075313-3841FF07-AE47-46E2-8E19-AAE1E6D26D22Q43173878-AB520AF6-9863-4EDA-B2BF-BF575325787AQ47552415-9834FDD1-01E6-4A69-9E95-882F86122411Q50957929-27DA4365-95C7-4CE0-8CB4-0A587E35945BQ53765659-A558214D-D33C-44AF-A52E-6D9BA519CA8CQ58800789-9138E038-FCC0-4E9A-B751-E573B81D0FC3
P2860
Nanocarriers for intravenous injection--the long hard road to the market.
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Nanocarriers for intravenous injection--the long hard road to the market.
@ast
Nanocarriers for intravenous injection--the long hard road to the market.
@en
Nanocarriers for intravenous injection--the long hard road to the market.
@nl
type
label
Nanocarriers for intravenous injection--the long hard road to the market.
@ast
Nanocarriers for intravenous injection--the long hard road to the market.
@en
Nanocarriers for intravenous injection--the long hard road to the market.
@nl
prefLabel
Nanocarriers for intravenous injection--the long hard road to the market.
@ast
Nanocarriers for intravenous injection--the long hard road to the market.
@en
Nanocarriers for intravenous injection--the long hard road to the market.
@nl
P1476
Nanocarriers for intravenous injection--the long hard road to the market
@en
P2093
Matthias Wacker
P356
10.1016/J.IJPHARM.2013.08.079
P407
P577
2013-09-12T00:00:00Z